CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

Majeti, Ravindra, Chao, Mark P., Alizadeh, Ash A., Pang, Wendy W., Jaiswal, Siddhartha, Gibbs, Kenneth D., van Rooijen, Nico, Weissman, Irving L.·2009·Cell
DOI 10.1016/j.cell.2009.05.045

Cited by (1,001)

Items 701–800 of 1,001

  1. CD9, a potential leukemia stem cell marker, regulates drug resistance and leukemia development in acute myeloid leukemia
    Yongliang Liu, Guiqin Wang, Jiasi Zhang, Xue Chen, Huailong Xu, Gang Heng, Jun Chen, Yongchun Zhao, Jiatao Li, Yuanli Ni et al. · 2021 · Stem Cell Research & Therapy
  2. Overexpression of CD47 is associated with brain overgrowth and 16p11.2 deletion syndrome
    Jingling Li, Thomas Brickler, Allison M. Banuelos, Kristopher David Marjon, Anna Shcherbina, Sravani Banerjee, Jing Tan Bian, Cyndhavi Narayanan, Irving L. Weissman, Sundari Chetty · 2021 · Proceedings of the National Academy of Sciences
  3. Autophagy proteins regulate cell engulfment mechanisms that participate in cancer
    Kim, Sung Eun, Overholtzer, Michael · 2013 · Seminars in Cancer Biology
  4. Immunotherapies of acute myeloid leukemia: Rationale, clinical evidence and perspective
    Yunyi Wu, Yanchun Li, Yan Gao, Ping Zhang, Qiangan Jing, Yinhao Zhang, Weidong Jin, Ying Wang, Jing Du, Gongqiang Wu · 2024 · Biomedicine & Pharmacotherapy
  5. Macrophage-specific in vivo RNA editing promotes phagocytosis and antitumor immunity in mice
    Yuxuan Chen, Xiaohong Chen, Yao Zhang, Meng Wang, Minqi Yang, R Y Wang, Xiaojie Yan, Shiyi Shao, Huhu Xin, Qida Hu et al. · 2025 · Science Translational Medicine
  6. “Marker of Self” CD47 on lentiviral vectors decreases macrophage-mediated clearance and increases delivery to SIRPA-expressing lung carcinoma tumors
    Nisha G. Sosale, Irena I. Ivanovska, Richard K Tsai, Joe Swift, Jake Hsu, Cory M. Alvey, Philip W. Zoltick, Dennis E. Discher · 2016 · Molecular Therapy — Methods & Clinical Development
  7. A function-blocking CD47 antibody modulates extracellular vesicle-mediated intercellular signaling between breast carcinoma cells and endothelial cells
    Sukhbir Kaur, ABDEL G. ELKAHLOUN, SATYA PRAKASH SINGH, Anush Arakelyan, David D. Roberts · 2017 · Journal of Cell Communication and Signaling
  8. Anti‐human SIRP α antibody is a new tool for cancer immunotherapy
    Yoji Murata, Daisuke Tanaka, Daisuke Hazama, Tadahiko Yanagita, Yasuyuki Saito, Takenori Kotani, Per‐Arne Oldenborg, Takashi Matozaki · 2018 · Cancer Science
  9. A SIRPα‐Fc fusion protein enhances the antitumor effect of oncolytic adenovirus against ovarian cancer
    Yao Qi Huang, Saiqun Lv, Pinyi Liu, Zhenlong Ye, Huan Yang, Linfang Li, Haili Zhu, Ying Wang, Lianzhen Cui, Duqing Jiang et al. · 2020 · Molecular Oncology
  10. Potential New Cancer Immunotherapy: Anti-CD47-SIRPα Antibodies
    Quansheng Lu, Xi Chen, Shan Wang, Lu Yu, Chunsheng Yang, Guan Jiang · 2020 · OncoTargets and Therapy
  11. CD47 expression and CD163+ macrophages correlated with prognosis of pancreatic neuroendocrine tumor
    Rami Imam, Qing Chang, Margaret A. Black, Caroline Yu, Wenqing Cao · 2021 · BMC Cancer
  12. The new progress in cancer immunotherapy
    Ajmeri Sultana Shimu, Hua-xing Wei, Qiangsheng Li, Xucai Zheng, Bofeng Li · 2022 · Clinical and Experimental Medicine
  13. New hope for tumor immunotherapy: the macrophage-related “do not eat me” signaling pathway
    Han Yu Deng, Guan Wang, Shengyan Zhao, Yiran Tao, Zhixiong Zhang, Jinliang Yang, Yi Lei · 2023 · Frontiers in Pharmacology
  14. Enhancing Cancer Chemo‐Immunotherapy: Innovative Approaches for Overcoming Immunosuppression by Functional Nanomaterials
    Jingjing Wang, Li Li, Zhi Ping Xu · 2023 · Small Methods
  15. Lactic acid in macrophage polarization: A factor in carcinogenesis and a promising target for cancer therapy
    Mobarakeh Ajam-Hosseini, Romina Heydari, Milad Rasouli, Fatemeh Akhoondi, Niloofar Asadi Hanjani, Sander Bekeschus, Mohammad Doroudian · 2024 · Biochemical Pharmacology
  16. Engineered Cellular Vesicles Displaying Glycosylated Nanobodies for Cancer Immunotherapy
    Jicheng Wu, Hailin Lu, Ximing Xu, Lang Rao, Yun Ge · 2024 · Angewandte Chemie International Edition
  17. TIM‐3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia
    Yoshikane Kikushige, Koichi Akashi · 2012 · Annals of the New York Academy of Sciences
  18. Rab27a Negatively Regulates Phagocytosis by Prolongation of the Actin-coating Stage around Phagosomes
    Yokoyama Kunio, Hiroaki Kaji, Jinsong He, Chisato Tanaka, Ryoichi Hazama, Takashi Kamigaki, Yonson Ku, Kaoru Tohyama, Yumi Tohyama · 2010 · Journal of Biological Chemistry
  19. Insights into CD47/SIRPα axis-targeting tumor immunotherapy
    Xuyao Zhang, Jiajun Fan, Dianwen Ju · 2018 · Antibody Therapeutics
  20. Dissecting the Immune Landscape of Acute Myeloid Leukemia
    Jan Kenneth Davidson-Moncada, Elena Viboch, SE Church, Sarah E. Warren, Sergio Rutella · 2018 · Biomedicines
  21. Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors
    Thomas W. Miller, Joshua Amason, Elsa D. Garcin, Laurence Lamy, Patricia K. Dranchak, Ryan MacArthur, John C. Braisted, Jeffrey S. Rubin, Teresa L. Burgess, Catherine L. Farrell et al. · 2019 · PLoS ONE
  22. SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells
    Siret Tahk, Binje Vick, Björn Hiller, Saskia Schmitt, Anetta Marcinek, Enrico D. Perini, Alexandra Leutbecher, Christian Augsberger, Anna Reischer, Benjamin Tast et al. · 2021 · Journal of Hematology & Oncology
  23. Modified exosomal SIRPα variants alleviate white matter injury after intracerebral hemorrhage via microglia/macrophages
    Xinjie Gao, Heng Yang, Weiping Xiao, Jiabin Su, Yuwen Zhang, He Wang, Wei Ni, Yuxiang Gu · 2022 · Biomaterials Research
  24. Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells
    Elvira Pelosi, Germana Castelli, Ugo Testa · 2015 · Blood Cells Molecules and Diseases
  25. The Ban on US Government Funding Research Using Human Fetal Tissues: How Does This Fit with the NIH Mission to Advance Medical Science for the Benefit of the Citizenry?
    J M McCune, Irving L. Weissman · 2019 · Stem Cell Reports
  26. Targeting Immunophenotypic Markers on Leukemic Stem Cells: How Lessons from Current Approaches and Advances in the Leukemia Stem Cell (LSC) Model Can Inform Better Strategies for Treating Acute Myeloid Leukemia (AML)
    Kelly Mitchell, Ulrich G. Steidl · 2019 · Cold Spring Harbor Perspectives in Medicine
  27. Third-Generation Anti-CD47-Specific CAR-T Cells Effectively Kill Cancer Cells and Reduce the Genes Expression in Lung Cancer Cell Metastasis
    Huyen Thi La, Dao Bich Thi Tran, Hai Manh Tran, Linh Trong Nguyen · 2021 · Journal of Immunology Research
  28. Suppressing or Enhancing Macrophage Engulfment through the Use of CD47 and Related Peptides
    AbdelAziz R. Jalil, Michael P. Tobin, Dennis E. Discher · 2022 · Bioconjugate Chemistry
  29. The Hippo-YAP signaling pathway drives CD24-mediated immune evasion in esophageal squamous cell carcinoma via macrophage phagocytosis
    Xiaofeng Zhou, Ziyi Yan, Jinghan Hou, Lichen Zhang, Zhen Chen, Can Gao, Nor Hazwani Ahmad, Mingzhou Guo, Weilong Wang, Tao Han et al. · 2024 · Oncogene
  30. The glycosyltransferase ST3GAL4 drives immune evasion in acute myeloid leukemia by synthesizing ligands for the glyco-immune checkpoint receptor Siglec-9
    Vignesh Krishnamoorthy, John M. Daly, Jimmy Kim, Lidia Piatnitca, Katie A. Yuen, Bhoj Kumar, Mehrnoush Taherzadeh Ghahfarrokhi, Thi Tho Bui, Parastoo Azadi, Ly Vu et al. · 2024 · Leukemia
  31. USP2 inhibition unleashes CD47-restrained phagocytosis and enhances anti-tumor immunity
    Panpan Dai, Yishuang Sun, Zhengrong Huang, Yu-Tong Liu, Minling Gao, Hai-Ming Liu, Jie Shi, Chuan Hua He, Bolin Xiang, Yingmeng Yao et al. · 2025 · Nature Communications
  32. CD244 maintains the proliferation ability of leukemia initiating cells through SHP-2/p27kip1 signaling
    Feifei Zhang, Xiao-Ye Liu, Chi-Qi Chen, Jun Zhu, Zhuo Yu, Jing-Jing Xie, Li Xie, Hai-Tao Bai, Yaping Zhang, Xia Fang et al. · 2017 · Haematologica
  33. Targeting CD157 in AML using a novel, Fc-engineered antibody construct
    Christina Krupka, Felix Sebastian Lichtenegger, Thomas Köhnke, Jan Boegeholz, Veit Bücklein, Michael Roiss, Torben Altmann, To Uyen Do, Rachel L. Dusek, Keith Wilson et al. · 2017 · Oncotarget
  34. Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled
    Jan Philipp Bewersdorf, Maximilian F. Stahl, Amer Methqal Zeidan · 2019 · Expert Review of Anticancer Therapy
  35. 3D bioprinting technology to mimic the tumor microenvironment: tumor-on-a-chip concept
    Hadi Samadian, S. Jafari, Mohammad Reza Sepand, Loghman Alaei, Soroor Sadegh Malvajerd, Mehdi Jaymand, Farbod Ghobadinezhad, Fatemeh Jahanshahi, Michael Richard Hamblin, Hossein Derakhshankhah et al. · 2021 · Materials Today Advances
  36. Recent advances in nanoparticles-based photothermal therapy synergizing with immune checkpoint blockade therapy
    Xinlun Dai, Xin Li, Yahui Liu, Fei Yan · 2022 · Materials & Design
  37. Significance of CD47 expression in gastric cancer
    Tomoya Sudo, Yusuke Takahashi, Genta Sawada, Ryutaro Uchi, Koshi Mimori, Yoshito Akagi · 2017 · Oncology Letters
  38. A Gene‐Editable Palladium‐Based Bioorthogonal Nanoplatform Facilitates Macrophage Phagocytosis for Tumor Therapy
    Shujun Feng, Yu Zhang, Yanfeng Gao, Yuta Liu, Yan‐Yi Wang, Xin Han, Tao Zhang, Yujun Song · 2023 · Angewandte Chemie International Edition
  39. A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors
    Cathy Eng, Nehal J. Lakhani, Philip A. Philip, Charles John Schneider, Benny Johnson, Adel Kardosh, Mark Ping Chao, Amita Patnaik, F. D. Shihadeh, Yeon‐Ju Lee et al. · 2025 · Targeted Oncology
  40. A post-transcriptional program of chemoresistance by AU-rich elements and TTP in quiescent leukemic cells
    Sooncheol Lee, Douglas Scott Micalizzi, Samuel Spencer Truesdell, Syed I. A. Bukhari, Myriam Boukhali, Jennifer Lombardi Story, Yasutaka Kato, Min‐Kyung Choo, Ipsita Dey‐Guha, Fei Ji et al. · 2020 · Genome biology
  41. A Novel Blockade CD47 Antibody With Therapeutic Potential for Cancer
    Fangzhen Lin, Mengshang Xiong, Hao Wei, Yuewen Song, Ruoqi Liu, Yuanyuan Yang, Xiangfei Yuan, Dongmei Fan, Yizi Zhang, Mu Hao et al. · 2021 · Frontiers in Oncology
  42. Macrophages in multiple myeloma: key roles and therapeutic strategies
    Khatora S. Opperman, Kate Vandyke, Peter James Psaltis, Jacqueline E. Noll, Andrew C.W. Zannettino · 2021 · Cancer and Metastasis Reviews
  43. Anti-CD47 Monoclonal Antibody–Drug Conjugate: A Targeted Therapy to Treat Triple-Negative Breast Cancers
    Yingnan Si, Ya Zhang, Jia-Shiung Guan, Hanh Giai Ngo, Angela Totoro, Ajeet Pal Singh, Kai Chen, Yuanxin Xu, Eddy Shih-Hsin Yang, Lufang Zhou et al. · 2021 · Vaccines
  44. Relapsed acute myeloid leukemia in children and adolescents: current treatment options and future strategies
    Sara Zarnegar‐Lumley, Kenneth J. Caldwell, Jeffrey E. Rubnitz · 2022 · Leukemia
  45. New Frontiers in Monoclonal Antibodies for the Targeted Therapy of Acute Myeloid Leukemia and Myelodysplastic Syndromes
    Marco Gallazzi, Maghalie Anais Marie Ucciero, Danilo Faraci, Abdurraouf Mokhtar Mahmoud, Wael Al Essa, Gianluca Gaïdano, Samir Mouhssine, Elena Crisà · 2022 · International Journal of Molecular Sciences
  46. Engineered proteins with sensing and activating modules for automated reprogramming of cellular functions
    Jie Sun, Lei Lei, Chih‐Ming Tsai, Yi Wang, Yiwen Shi, Mingxing Ouyang, Shaoying Lu, Jihye Seong, Tae‐Jin Kim, Pengzhi Wang et al. · 2017 · Nature Communications
  47. Innovative Medicine
    Kazuwa Nakao, Nagahiro Minato, Shinji Üemoto · 2015 · Springer eBooks
  48. Is targeting of CD47-SIRPα enough for treating hematopoietic malignancy?
    Xi Wen Zhao, Taco Willem Kuijpers, Timo K. van den Berg · 2012 · Blood
  49. m1A inhibition fuels oncolytic virus-elicited antitumor immunity via downregulating MYC/PD-L1 signaling
    Shu‐Jin Li, Feng Tian, Yuan‐Tong Liu, Qi‐Chao Yang, An Song, Shuo Wang, Jun Xie, Junjie Zhang, Bi‐Feng Yuan, Zhi‐Jun Sun · 2024 · International Journal of Oral Science
  50. M 6 A‐mediated upregulation of lncRNA TUG1 in liver cancer cells regulates the antitumor response of CD8 + T cells and phagocytosis of macrophages
    Qing Xi, Guangze Yang, Xue He, Hao Zhuang, Li Li, Lin Bing, Lingling Wang, Xianyang Wang, Chunqiang Fang, Qiurui Chen et al. · 2024 · Advanced Science
  51. Molecular pathways to CML stem cells
    Kristen N. Rice, Catriona H. M. Jamieson · 2010 · International Journal of Hematology
  52. DNA Damage: A Sensible Mediator of the Differentiation Decision in Hematopoietic Stem Cells and in Leukemia
    Cary N. Weiss, Keisuke Ito · 2015 · International Journal of Molecular Sciences
  53. Anti-CD117 immunotherapy to eliminate hematopoietic and leukemia stem cells
    Norman F. Russkamp, Renier Myburgh, Jonathan D. Kiefer, Dario Neri, Markus Gabriel Manz · 2021 · Experimental Hematology
  54. Hot or cold: Bioengineering immune contextures into in vitro patient-derived tumor models
    Nathaniel Sheng Hua Too, Nicholas Ching Wei Ho, Christabella Adine, Narayanan Gopalakrishna Iyer, Eliza Li Shan Fong · 2021 · Advanced Drug Delivery Reviews
  55. Targeting CD47/SIRPα in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Preclinical and Clinical Developments of Magrolimab
    Fadi Haddad, Naval Guastad Daver · 2021 · Journal of Immunotherapy and Precision Oncology
  56. Targeting Mitochondrial Oxidative Phosphorylation Eradicates Acute Myeloid Leukemic Stem Cells
    Meixi Peng, Yongxiu Huang, Ling Zhang, Xueya Zhao, Yu Hou · 2022 · Frontiers in Oncology
  57. Loss of CD47 alters CD8+ T cell activation in vitro and immunodynamics in mice
    Pulak Ranjan Nath, Dipasmita Pal-Nath, Sukhbir Kaur, Arunkumar Gangaplara, Thomas Joshua Meyer, Margaret C. Cam, David D. Roberts · 2022 · OncoImmunology
  58. The role of PD-1/PD-L1 axis in idiopathic pulmonary fibrosis: Friend or foe?
    Aimin Jiang, Na Liu, Jingjing Wang, Xiaoqiang Zheng, Mengdi Ren, Wei Zhang, Yu Yao · 2022 · Frontiers in Immunology
  59. Review Article: CD47 in xenograft rejection and tolerance induction
    Yong‐Guang Yang · 2010 · Xenotransplantation
  60. SIRPα/CD172a and FHOD1 Are Unique Markers of Littoral Cells, a Recently Evolved Major Cell Population of Red Pulp of Human Spleen
    Javier Gordon Ogembo, Danny A. Milner, Keith G. Mansfield, Scott J. Rodig, Gëorge F. Murphy, Jeffery Lorne Kutok, Geraldine S. Pinkus, Joyce D. Fingeroth · 2012 · The Journal of Immunology
  61. Reactive oxygen species in eradicating acute myeloid leukemic stem cells.
    Hui Zhang, Hai Fang, Kankan Wang · 2014 · Europe PMC (PubMed Central)
  62. EpCAM Inhibition Sensitizes Chemoresistant Leukemia to Immune Surveillance
    Xiaohu Zheng, Xiaolei Fan, Binqing Fu, Meijuan Zheng, Aimei Zhang, Kai Long Zhong, Jialai Yan, Rui Sun, Zhigang Tian, Haiming Wei · 2016 · Cancer Research
  63. Death begets a new beginning
    Lidia Bosurgi, Lindsey D. Hughes, Carla Vanina Rothlin, Sourav Ghosh · 2017 · Immunological Reviews
  64. Surface Modification of Macrophages with Nucleic Acid Aptamers for Enhancing the Immune Response against Tumor Cells
    Shunsuke Sugimoto, Yasuhiko Iwasaki · 2018 · Bioconjugate Chemistry
  65. Combinations of HDAC Inhibitor and PPAR Agonist Induce Ferroptosis of Leukemic Stem Cell–like Cells in Acute Myeloid Leukemia
    Hui Zhou, Dongmei Qin, Chendi Xie, Jie Zhou, Shuman Jia, Ziwei Zhou, Yi Qiu, Bing Xu, Jie Zha · 2024 · Clinical Cancer Research
  66. The AML immune paradox: decoding escape pathways and pioneering checkpoint, vaccine, and combination strategies
    Hamed Soleimani Samarkhazan, Fatemeh Sadat Shafiei, Zahra Taghinejad, Mohsen Maleknia, Hanieh Noormohamadi, Atieh Raoufi, Sina Nouri · 2025 · Clinical and Experimental Medicine
  67. Identifying leukemia stem cells – Is it feasible and does it matter?
    Christoph Lutz, Van Thanh Hoang, Eike C. Buss, Anthony Dick Ho · 2012 · Cancer Letters
  68. Ara-C and anti-CD47 antibody combination therapy eliminates acute monocytic leukemia THP-1 cells in vivo and in vitro
    Y. Wang, C. Yin, Long Feng, Chunru Wang, G. Sheng · 2015 · Genetics and Molecular Research
  69. Endoglin: a novel target for therapeutic intervention in acute leukemias revealed in xenograft mouse models
    Keina Maciele Campos Dourado, June Baik, Vanessa K.P. Oliveira, Miriam Perlingeiro Beltrame, Ami Yamamoto, Charles P. Theuer, Camila Alexandrina Figueiredo, Michael R. Verneris, Rita C. R. Perlingeiro · 2017 · Blood
  70. Treatment of Acute Myeloid Leukemia in the Era of Genomics—Achievements and Persisting Challenges
    Steven Daniel Green, Heiko Koenig · 2020 · Frontiers in Genetics
  71. Microglia-Centered Combinatorial Strategies Against Glioblastoma
    Tomás A. Martins, Philip Schmassmann, Tala Shekarian, Jean‐Louis Boulay, Marie‐Françoise Ritz, Saeid Zanganeh, Johannes vom Berg, Gregor Hütter · 2020 · Frontiers in Immunology
  72. Targeting CD47 as a Novel Immunotherapy for Breast Cancer
    Can Chen, Runlu Wang, Xi Chen, Yulong Hou, Jingting Jiang · 2022 · Frontiers in Oncology
  73. Acute Myelogenous Leukemia and its Microenvironment: A Molecular Conversation
    Gabriel Ghiaur, Mark Wroblewski, Sonja Loges · 2015 · Seminars in Hematology
  74. Enhanced ADCC Activity of Affinity Maturated and Fc-Engineered Mini-Antibodies Directed against the AML Stem Cell Antigen CD96
    Sahar Mohseni Nodehi, Roland Repp, Christian Kellner, Joachim Bräutigam, Matthias Staudinger, Natalie Schub, Matthias Peipp, Martin Gramatzki, Andreas Humpe · 2012 · PLoS ONE
  75. Leishmania donovani‐induced expression of signal regulatory protein α on Kupffer cells enhances hepatic invariant NKT‐cell activation
    Lynette Beattie, Mattias Svensson, Alison J. Bune, Najmeeyah Brown, Asher Maroof, Soombul Zubairi, Katharine R. Smith, Paul Martin Kaye · 2009 · European Journal of Immunology
  76. Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia
    Max Jan, Thomas M. Snyder, M. Ryan Corces, Irving L. Weissman, Stephen R. Quake, Ravindra Majeti · 2011 · Blood
  77. SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells
    Laia Pascual Ponce, Nadja C. Fenn, Nadine Moritz, Christina Krupka, Jan-Hendrik Kozik, Kirsten Lauber, Marion S. Subklewe, Karl‐Peter Hopfner · 2017 · Oncotarget
  78. The identification of a CD47-blocking “hotspot” and design of a CD47/PD-L1 dual-specific antibody with limited hemagglutination
    Rui Shi, Yan Chai, Xiaomin Duan, Xiaoshan Bi, Qingrui Huang, Qihui Wang, Shuguang Tan, George F. Gao, Jianhua Zhu, Jinghua Yan · 2020 · Signal Transduction and Targeted Therapy
  79. Chimeric antigen receptors that trigger phagocytosis
    Meghan A. Morrissey, Adam P. Williamson, Adriana M. Steinbach, Edward W. Roberts, Nadja Kern, Mark B. Headley, Ronald D. Vale · 2018 · bioRxiv (Cold Spring Harbor Laboratory)
  80. Systematic evaluation of AML-associated antigens identifies anti-U5 SNRNP200 therapeutic antibodies for the treatment of acute myeloid leukemia
    Katherine L. B. Knorr, Jahan A. Rahman, Caroline Erickson, Eric Wang, Mara Monetti, Zhuoning Li, Juliana Ortiz-Pacheco, Andrew Jones, Sydney X. Lu, Robert F. Stanley et al. · 2023 · Nature Cancer
  81. Addressing the Inflammatory Response to Clinically Relevant Polymers by Manipulating the Host Response Using ITIM Domain-Containing Receptors
    Joshua B. Slee, Abigail J. Christian, Robert J. Levy, Stanley J. Stachelek · 2014 · Polymers
  82. The extracellular matrix: A key player in the pathogenesis of hematologic malignancies
    Ishnoor Sidhu, Sonali P. Barwe, Anilkumar Gopalakrishnapillai · 2020 · Blood Reviews
  83. Promoters and Antagonists of Phagocytosis: A Plastic and Tunable Response
    Spencer A. Freeman, Sergio Grinstein · 2021 · Annual Review of Cell and Developmental Biology
  84. Harnessing Macrophages through the Blockage of CD47: Implications for Acute Myeloid Leukemia
    Luciana Melo Garcia, Frédéric Barabé · 2021 · Cancers
  85. Blocking CD47-SIRPα Signal Axis as Promising Immunotherapy in Ovarian Cancer
    Xukai Luo, Yini Shen, Wu Huang, Yiting Bao, Jiahang Mo, Liangqing Yao, Lei Yuan · 2023 · Cancer Control
  86. Chimeric Peptide Engineered Bioregulator for Metastatic Tumor Immunotherapy through Macrophage Polarization and Phagocytosis Restoration
    Xia‐Yun Chen, Meng-Yi Yan, Qianqian Liu, Bai-Xue Yu, Yi Cen, Shiying Li · 2023 · ACS Nano
  87. Extinction models for cancer stem cell therapy
    Mary Elizabeth Sehl, Hua Zhou, Janet S. Sinsheimer, Kenneth L. Lange · 2011 · Mathematical Biosciences
  88. Progress in Adaptive Immunotherapy for Cancer in Companion Animals: Success on the Path to a Cure
    Katie Anderson, Jaime F. Modiano · 2015 · Veterinary Sciences
  89. Cord blood stem cell derived CD16+ NK cells eradicated acute lymphoblastic leukemia cells using with anti-CD47 antibody
    Behnaz Valipour, Ali Abedelahi, Elahe Naderali, Kobra Velaei, Ali Akbar Movassaghpour, Mehdi Talebi, Soheila Montazersaheb, Mohammad Karimipour, Masoud Darabi, Hadi Chavoshi et al. · 2019 · Life Sciences
  90. Immunity to stemness genes in human cancer
    Madhav V. Dhodapkar · 2010 · Current Opinion in Immunology
  91. Biomimetic Nano‐Degrader Based CD47‐SIRPα Immune Checkpoint Inhibition Promotes Macrophage Efferocytosis for Cardiac Repair
    Jinfeng Gao, Zhiqing Pang, Qiaozi Wang, Yiwen Tan, Qiyu Li, Haipeng Tan, Jing Chen, Wusiman Yakufu, Zhengmin Wang, Hongbo Yang et al. · 2024 · Advanced Science
  92. Metabolic reprograming mediated by tumor cell-intrinsic type I IFN signaling is required for CD47-SIRPα blockade efficacy
    Hang Zhou, Wenjun Wang, Hairong Xu, Yong Liang, Jiyu Ding, Mengjie Lv, Boyang Ren, Hua Peng, Yang‐Xin Fu, Mingzhao Zhu · 2024 · Nature Communications
  93. Tackling molecular targets beyond PD-1/PD-L1: Novel approaches to boost patients’ response to cancer immunotherapy
    Hany A. Omar, Mai Fathy Tolba · 2019 · Critical Reviews in Oncology/Hematology
  94. Hydrogen gas represses the progression of lung cancer via down-regulating CD47
    Jinghong Meng, Leyuan Liu, Dongchang Wang, Zhenfeng Yan, Gang Chen · 2020 · Bioscience Reports
  95. Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody
    Haiqing Ni, Lei Cao, Zhihai Wu, Li Wang, Shuaixiang Zhou, Xiaoli Guo, Yarong Gao, Jing Hua, Min Huan Wu, Yang Liu et al. · 2021 · Cancer Immunology Immunotherapy
  96. Overcoming immunotherapeutic resistance in PDAC: SIRPα-CD47 blockade
    Abdullahi Opeyemi Alausa, Khadijat Ayodeji Lawal, Oluwakemi Arinola Babatunde, E. N. O. Obiwulu, Olajumoke Christianah Oladokun, Olumide Samuel Fadahunsi, Ugwu Obiora Celestine, Emmanuel Ugbede Moses, Ifunanya Rejoice Akaniro, Peter Ifeoluwa Adegbola · 2022 · Pharmacological Research
  97. The Glycosylation of Immune Checkpoints and Their Applications in Oncology
    Linlin Zheng, Qi Yang, Feifei Li, Min Zhu, Haochi Yang, Tian Tan, Binghuo Wu, Ming-Xin Liu, Chuan Xu, Jun Yin et al. · 2022 · Pharmaceuticals
  98. Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives
    Longchao Liu, Jiahui Chen · 2022 · Medical Review
  99. Combined GLUT1 and OXPHOS inhibition eliminates acute myeloid leukemia cells by restraining their metabolic plasticity
    Maria Rodriguez‐Zabala, Ramprasad Ramakrishnan, Katrin Reinbach, Somadri Ghosh, Leal Oburoglu, Ton Falqués, Kishan Bellamkonda, Mats Ehinger, Pablo Peña‐Martínez, Noelia Puente‐Moncada et al. · 2023 · Blood Advances
  100. Hierarchical organization and regulation of the hematopoietic stem cell osteoblastic niche
    Hongxu Wang, Penghui Zhang, Lin Liu, Lin Zou · 2012 · Critical Reviews in Oncology/Hematology